CAD Therapeutics, Inc. — SEC Form D Filing

CAD Therapeutics, Inc. filed an SEC Form D on October 2, 2026, reporting $4.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 2, 2026
Amount reported
$4.00M
Round stage
Series A because the company raised $4,000,000 through the issuance of Series A common stock to fund its early-stage clinical development.
Industry
Biotechnology
Website
https://cadtherapeutics.com

What the company does

Securities: Equity, SERIES A COMMON STOCK. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffering from critical-care cardiovascular conditions and heparin-induced thrombocytopenia lack safe and effective targeted anticoagulation therapies.

Solution

CAD Therapeutics develops novel cardiovascular therapies, including CAD-1005 and tecarfarin, to address acute kidney injury and provide chronic anticoagulation.

Why now

The rising global prevalence of cardiovascular diseases combined with recent regulatory pathways for orphan drug designations has created an urgent demand for specialized cardiovascular therapies.

Source: SEC EDGAR Form D filing